Several studies have shown that LAPTM4B overexpression is associated with tumorigenesis and metastatic progression in different cancers, such as hepatocellular carcinoma (HCC) [44], breast cancer [45], ovarian carcinoma [46], and gastric cancer [47]. Here, LAPTM4B is linked to gastric cancer.